瑞普生物(300119.SZ):子公司獲得發明專利證書
格隆匯 5 月 10日丨瑞普生物(300119.SZ)公佈,公司全資子公司瑞普(保定)生物藥業有限公司近日獲得由國家知識產權局頒發的發明專利證書,具體如下:

該專利開發了一種新型的禽腺病毒Hexon與雞傳染性法氏囊病病毒VP2亞單位疫苗的製備方法,其採用基因工程發酵方式製備禽腺病毒Hexon與雞傳染性法氏囊病病毒VP2融合抗原,與免疫佐劑混合乳化製成二聯基因工程亞單位疫苗,可同時免疫預防禽腺病毒病和雞傳染性法氏囊病,為公司新型獸用疫苗的開發奠定了基礎。
該專利的獲得不會對公司生產經營產生重大影響,但體現了公司重組亞單位疫苗的自主創新能力,進一步完善公司在該領域的知識產權保護體系,提升公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.